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Abstract
Background: Proteomics may help us better understand the changes of multiple proteins involved in oncogenesis
and progression of prostate cancer(PCa) and identify more diagnostic and prognostic biomarkers. The aim of this
study was to screen biomarkers of PCa by the proteomics analysis using isobaric tags for relative and absolute
quantification(iTRAQ).
Methods: The patients undergoing prostate biopsies were classified into 3 groups according to pathological
results: benign prostate hyperplasia (BPH, n = 20), PCa(n = 20) and BPH with local prostatic intraepithelial neoplasm
(PIN, n = 10). Then, all the specimens from these patients were analyzed by iTRAQ and two-dimensional liquid
chromatography-tandem mass spectrometry (2DLC-MS/MS). The Gene Ontology(GO) function and the transcription
regulation networks of the differentially expressed were analyzed by MetaCore software. Western blotting and
Immunohistochemical staining were used to analyze the interesting proteins.
Result: A total of 760 proteins were identified from 13787 distinct peptides, including two common proteins
that enjoy clinical application: prostate specific antigen (PSA) and prostatic acid phosphatase(PAP). Proteins
that expressed differentially between PCa and BPH group were further analyzed. Compared with BPH, 20
proteins were significantly differentially up-regulated (>1.5-fold) while 26 were significantly down-regulated in
PCa(<0.66-fold). In term of GO database, the differentially expressed proteins were divided into 3 categories:
cellular component(CC), molecular function (MF) and biological process(BP). The top 5 transcription regulation
networks of the differentially expressed proteins were initiated through activation of SP1, p53, YY1, androgen
receptor(AR) and c-Myc The overexpression of periostin in PCa was verified by western blotting and
immunohistochemical staining.
Conclusion: Our study indicates that the iTRAQ technology is a new strategy for global proteomics analysis of the
tissues of PCa. A significant up-regulation of periostin in PCa compared to BPH may provide clues for not only a
promising biomarker for the prognosis of PCa but also a potential target for therapeutical intervention.
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Prostate cancer(PCa) is the most common cancer and the
second leading cause of cancer-related deaths among
men in the USA and Europe [1]. It has been estimated
that in the USA alone over 192,000 men will be diag-
nosed with PCa in 2009, causing over 27, 000 deaths [2].
For reasons largely unknown, the incidence of PCa, even
when corrected by new widespread testing of serum
prostate specific antigen (PSA) has increased in the last
two decades [3]. In China, the mortality of prostate can-
cer also increases every year. A raised PSA level and/or
an enlarged or irregular gland on digital rectal examina-
tion are used to decide whether transrectal ultrasound
-guided biopsy is needed to diagnose PCa [4].
But, PSA can be secreted from benign as well as
malignant cells of the prostate so the PSA level is not
PCa-specific as it may also be elevated in benign pros-
tate hyperplasia(BPH) and prostatitis [5]. Clinically, 4.0
ng/ml of PSA level is considered as the cutoff value.
But, approximately 15% of men with PSA level below 4
ng/ml suffer prostate cancer too. Additionally, it is diffi-
cult to distinguish PCa from BPH when PSA level is in
the range of 4 to 10 ng/ml known as “diagnostic gray
zone”. For men with PSA level of 4 to 10 ng/ml, there is
about a 25% chance of having PCa [6]. So, PSA presents
suboptimum sensitivity and specificity as an early stage
marker [7]. Furthermore, Men with PSA level above 4
ng/ml with the diagnosis of BPH confirmed by prostate
biopsies still require annual serum test of PSA and
repeated biopsies to exclude PCa. It is necessary to
develop better means for early diagnosis of PCa [8]. In
addition, we are rendered with few effective means to
screen patients with potential disease progression who
require early intervention from clinically localized PCa
[8]. Therefore, the molecular mechanisms of the onco-
genesis and progression of PCa needs to be understood
in an effort to find new promising biomarkers to make
early diagnosis and intervention.
The molecular mechanisms of the development and
progression of PCa are complicated and likely to involve
multiple factors [9]. In the “seed and soil” hypothesis, it
has been pointed out that the interaction between
tumor cells and microenvironment plays an important
role in oncogenesis and cancer progression [10]. Estab-
lishment, growth, and invasion of PCa are supported by
this interaction or so called crosstalk in recent studies
[11]. Additionally, prostatic intraepithelial neoplasm
(PIN) characterized by cellular proliferation within pre-
existing ducts, ductules and glands, with cytological
changes similar to cancer including nucleus and nucleo-
lar enlargement will be identified in up to 16% of men
who have undergone prostate biopsies [12]. More and
more studies indicate that high-grade PIN is a premalig-
nant prostate lesion [13]. PCa develops in a series of
morphologic and genetic steps that begins with the
transformation of normal tissues into hyperplastic
lesions, and later into high-grade PIN, invasion and
metastasis [14].
Proteomics may help us better understand the changes
of multiple proteins involved in oncogenesis and cancer
progression and identify more diagnostic and prognostic
biomarkers [15]. Quantitative proteomics is an impor-
tant branch of proteomics which is applied to quantify
a n di d e n t i f ya l lt h ep r o t e i n se x p r e s s e db yaw h o l eg e n -
ome or in a complex mixture. Isobaric tags for relative
and absolute quantification(iTRAQ) was developed by
Applied Biosystems Incorporation in 2004. It labels glo-
bal peptide, preserves post-translational modification
information and makes quantitative proteomics analysis
of 4 samples simultaneously under the same experimen-
tal conditions, compared with other approaches such as
2-DE(two-dimensional gel electrophoresis), ICAT (iso-
top-ecoded affinity tags) and SILAC (stable isotope
labeling by amino acids in cell culture) [16,17]. This
unique approach labels samples with four independent
isobaric tags of the same mass that, upon fragmentation
in MS/MS, give rise to four unique reporter ions (m/z
from 114 to 117) that provide quantitative information
upon integration of the peak areas to quantify the four
different samples, respectively [17].
In this study, we analyzed the samples of prostate
biopsies from the patients with PCa, BPH, BPH with
local PIN by iTRAQ combined with 2DLC-MS/MS
(two-dimensional liquid chromatography-tandem mass
spectrometry) to find the biomarkers which may contri-
bute to the early diagnosis and prognosis of PCa. 46
proteins were found to demonstrate consistent differen-
tial expression between the BPH and PCa samples,
among which periostin has been studied in more detail
and revealed to be a promising marker of PCa.
Methods
Reagents and apparatus
The iTRAQ™ Reagents Kit was from Applied Biosys-
tems (USA). The trypsilin, acetonitrile, isopropanol,
acetone, formic acid, glycerol, sodium citrate buffer
were from Sigma-Aldrich(USA). KCl, KH2PO4, NaCl,
Tris, EDTA, Triton X-100, SDS were obtained from
Sinopharm Chemical Reagent Co, Ltd (Shanghai,
China). All buffers were prepared with the ultrapure
water generated from the Milli-Q system (Millipore,
USA). The Sep-Pak Vac C18 cartridges was from Milli-
pore Corporation(USA). 20AD HPLC system (Shimadzu,
Japan). The Polysulfoethyl column (2.1 × 100 mm, 5
μm, 300Å; The Nest Group, Southborough, MA), the
Zorbax 300SB-C18 reversed-phase column (0.1 × 150
mm, 5 μm ,3 0 0Å ;M i c r o m ,A u b u r n ,C A )a n dQ S T A R
XL System (Applied Biosystem, USA) were used for 2D
Sun et al. Proteome Science 2011, 9:22
http://www.proteomesci.com/content/9/1/22
Page 2 of 11LC-MS/MS. A rabbit polyclonal antibody of periostin
was purchased from Abcam(UK).
Clinical samples
A total of 11 biopsies have been collected from each of
the patients with elevated PSA level or irregular glands
by the department of Urology, Huashan Hospital of
Fudan University. From these, 10 biopsies were used for
standard pathological evaluation and one randomly cho-
sen biopsy from each patient was snap frozen with Tis-
sue-Tek OCT compound in liquid nitrogen, then stored
at -80°C until use. The histopathological characteristic
was evaluated after standard preparation of 5 μmt h i c k ,
formalin fixed paraffin embedded sections, stained with
hematoxylin and eosin(HE). After pathological evalua-
tion, the patients were categorized in three groups: BPH
Group comprised of 20 patients who were diagnosed as
BPH with a mean age 67.5 ± 8.8years, mean serum PSA
12.2 ± 6.5 ng/ml. PCa Group included 20 patients who
had a diagnosis of PCa with a mean age 70.5 ± 10.6
years, mean serum PSA 26.2 ± 14.0 ng/ml. BPH with
local PIN Group had 10 patients diagnosed as BPH with
local PIN with a mean age 69.6 ± 10.3years, mean
serum PSA 10.3 ± 3.7 ng/mL (range 3.2-19). The PCa
group contained 5 patients with PSA level above 20 ng/
ml, so, the mean level of PSA in PCa group is higher
than that in the other two groups. The study was
approved by the local ethics committee of Huashan
Hospital of Fudan University.
Protein preparation and iTRAQ labeling
The eluant of protein samples from the tissues of three
groups were quantitated by the Bradford method [18].
The iTRAQ labeling was performed according to the kit
prot- ocol. Briefly, 100 μg proteins of each group were
precipitated with cold acetone for 1 hour at -20°C and
resuspended in 20 μl dissolution buffer. After protein
reduction and alkylation followed by overnight digestion
with trysilin, the peptides were labeled with the iTRAQ
regents for 1 hour at room temperature. The iTRAQ
regents 114,116 and 117 were used to label the peptides
from BPH, PCa and BPH with local BPH respectively.
Then the samples were mixed, desalted with Sep-Pak
Vac C18 cartridges and dried in a vacuum centrifuge.
2D LC-MS/MS Analysis
The iTRAQ labeling mixed peptides were fractionated
by strong cation exchange chromatography (SCX) on a
20AD HPLC system using a Polysulfoethyl column. The
peptide mixture was reconstituted in Buffer A(10 mM
KH2PO4 in 25% acetonitrile, PH 2.6) and loaded onto
the column. The peptides were separated at a flow rate
of 200 μl/min for 60 min with a gradient of 0-80% Buf-
fer B (Buffer B was Buffer A containing 350 mM KCl)
in Buffer A. The absorbance of 214 nm and 280 nm was
monitored and a total of 20 SCX fractions were col-
lected. The fractions were vacuum dried and then resus-
pended in 50 μl HPLC Buffer A (5% acetonitrile, 0.1%
formic acid), loaded across the Zorbax 300 SB-C18
reversed-phase column and analyzed on a QSTAR XL
System coupled with a 20AD HPLC system. The flow
rate of elution was 0.3 μl/min with gradient 5%-35%
HPLC Buffer B (95% acetonitrile, 0.1% formic acid) for
90 min. The survey scans were obtained with m/z
ranges of 400-1800 for MS with up to three precursors
selected from m/z 100-2000 for MS/MS.
Data analysis
The MS/MS data were searched against the Interna-
tional Swissprot (090210, Human) using the Protein
Pilot software (version 3.0, revision 114732, Applied Bio-
system, USA) for peptide identification and quantifica-
tion. The parameters were set as follows:trypsilin as
enzyme, methylmethanethiosulphonate of cysteines resi-
dues as fixed modification. The Paragon Algorithm
(Applied Biosystem, USA) followed by the ProGroup
Algorithm (Applied Biosystem, USA) were applied to
remove redundant hits to determine the target proteins.
Other parameters such as parent ion accuracy, fragment
ion mass accuracy, tryptic cleavage specificity, and
allowance for number of missed cleavages were provided
and processed by ProteinPilot software. Unused Prot-
Score >1.3 (95%) as threshold with at least more than
one peptide above the 95% confidence was considered
as benchmark for protein identification. The relative
expression of proteins was based on the ratio of the
reporter ions of the peptides(116:114 or 116:117). We
adopted the fold change of the differentially expressed
proteins in the study by Glen et al and the fold change
cutoff ratio < 0.66 or >1.50 was selected to designate
proteins of differential expression (P < 0.05)[19]. The
cellular component (CC), molecular function (MF) and
biological process(BP) of the selected proteins were
a n n o t a t e db yG e n eO n t o l o g y( G O )d a t a b a s e .T h et r a n -
scription regulation networks of the differentially
expressed proteins were generated by MetaCore soft-
ware using a transcription regulation algorithm. The
networks were ranked by a P-value and interpreted in
terms of GO.
Western blotting
To verify periostin expression changes, 5 fresh tissue-
samples of BPH and 5 fresh tissue-samples of PCa were
analyzed by Western blotting. The tissue samples were
lysed in the protein extraction buffer (150 mM NaCl, 10
mM Tris(pH 7.2), 5 mM EDTA, 0.1% Triton X-100, 5%
glycerol, and 2% SDS) after tripsis in liquid nitrogen and
then incubated at 4°C for 30 min. After centrifugation at
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sue homogenate was determined using Bradford assay.
Proteins were denatured in sample buffer containing 2-
mercaptoethanol and bromophenol blue for 10 min at
95°C. Equal amount of proteins (50 ug) was fractionated
using 8 or 12% SDS-PAGE and transferred to PVDF
membranes. After blocking with 5% non-fat milk, the
membranes were incubated overnight at 4°C with the pri-
mary antibody. Then, the membranes washed with PBS
three times were incubated in secondary antibody at
room temperature. The intensity of target protein was
detected using the enhanced chemiluminescence detec-
tion system.
Immunohistochemical staining
Immunohistochemical staining was performed to evalu-
ate the expression of periost-in in 20 paraffin-specimens
of BPH and 20 paraffin-specimens of PCa. Each slide
was deparaffinized and rehydrated according to standard
protocol, and treated with 10 mM sodium citrate buffer
in a microwave pressure cooker at 120°C for 15 min.
Sections were then immersed in 3% hydrogen peroxide
and nonspecified binding was blocked in 5% normal
goat serum. A polyclonal anti-periostin was diluted
1:100. Immunohisto-chemical staining was conducted
following the avidin-biotin peroxidase complex met-hod
with diaminobenzidine as a chromogen. Slides were
counterstained with haemat-oxylin, dehydrated and
mounted. Brown cytoplasmic staining of stromal or
epithelial cells was considered positive. Cytoplasmic and
stromal reactivity were analyzed sep-arately. Chi square
test was applied to assess the statistical significance of
p e r i o s t i ne x p r e s s i o ni nt w og r o u p s .P - v a l u e<0 . 0 5w a s
considered significant.
Results
Based on the condition of protein identification:
Unused ProtScore >1.3(95%) as threshold with at least
more than one peptide above the 95% confidence, a
total of 760 proteins were identified from 13787 dis-
tinct peptides. 62% proteins were identified with at
least two peptides and 42% proteins were identified
with three or more peptides. Actin, gamma-enteric
smooth muscle (P63267, Human) was identified with
the most peptides above the 95% confidence. There
are 191 qualified peptides covering 72.6% of the Actin
protein sequence. Among the 760 proteins, PSA
(P07288, Human) and Prostatic acid phosphatase
(PAP, P15309, Human) were common proteins enjoy-
ing clinical application, with the former identified
with 11 peptides and the latter 4 peptides above the
95% confidence. Figure 1 and 2 show identification
and relative quantitation of peptides from PSA and
PAP, respectively.
In term of GO database, the differentially expressed
proteins were divided into 3 categories: CC, MF and BP.
The top 5 components for CC were extracellular matrix,
proteinaceous extracellular matrix, extracellular region,
extracellular region part and extracellular matrix part.
The top 5 components for MF were protein binding,
binding, misfolded protein binding, structural molecule
activity and enzyme binding. The top 5 components for
BP were muscle contraction, muscle system process,
cytoskeleton organization, anti-apoptosis and cell adhe-
sion (Figure 3). The transcription regulation networks
were ranked in term of the enrichment of the differen-
tially expressed proteins(P-value), rendering the top 5
networks to be the regulation initiated through activa-
tion of SP1, p53, YY1, androgen receptor(AR) and c-
Myc which were involved in the biological process such
as regulation of apoptosis, regulation of cell adhesion,
regulation of cellular component organization, response
to protein stimulus, etc(The transcription regulation
network of SP1 is shown in Figure 4)
Based on the condition of screening differential pro-
teins and compared the BPH samples 114 labeled, 20
proteins were significantly differentially up-regulated
and 26 were significantly down-regulated in PCa 116
labeled. Then, from the relative ratio between 116(PCa)
and 117(BPH with local PIN), 33 differential proteins
can be obtained including 19 up-regulated proteins and
14 down-regulated proteins in PCa. Interestingly, 11 up-
regulated proteins and 8 down-regulated proteins were
same between the differentially expressed proteins of
two sets. In this study, the relative ratio between 116
and 114 was mainly discussed and the differentially
expressed proteins were listed in Table 1. Whereas the
differentially expressed proteins of PCa compared with
BPH with local PIN (116:117) were listed in Table 2.
Many of them such as Tumor protein D52, Prohibitin-2,
Nucleophosmin, Elongation factor Tu(EF-Tu) have been
previously reported as differentially expressed in PCa
and closely related to oncogenesis and cancer progres-
sion [15,20-22]. Interestingly, the down-regulated pro-
teins in our study included several differentiation
markers of smooth muscle(SM) such as Desmin, Vimen-
tin, Actin, gamma-enteric smooth muscle, Laminin sub-
unit gamma-1, Vinculin which were studied by Wong
et al [23]. Our results of down-regulated proteins were
consistent with the changes of the SM differentiation
markers from their study.
Among the identified proteins, periostin was an inter-
esting protein showing up-regulation in PCa and was
further studied. Figure 5A shows the identified informa-
tion of periostin. The expression of periostin was verified
by western blotting. The results revealed a significant
increase of periostin amount in PCa compared to BPH
(Figure 5C). Furthermore, immunohistochemical staining
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stromal or epithelial cells of prostate (Figure 5B). Benign
prostate glands expressed positive stromal periostin in
only 5/20 cases and positive epithelial periostin in 8/20
cases. The stroma of PCa was positive in 16/20 cases and
the epithelium of PCa was positive in 12/20 cases. Statis-
tical significance was observed for the stromal expression
of periostin between PCa and BPH(P < 0.01). However,
there was no statistical significance for the epithelial
expression of periostin between PCa and BPH (Table 3).
Discussions
Although PSA has played a great role in diagnosing
PCa, the sensitivity and specificity of PSA have been
questioned by more and more studies [5-7]. So, many
researchers have applied the proteomic technologies to
search for new biomarkers, furthermore, a large number
of differentially expressed proteins have been identified
and some were reported as potential biomarkers for
diagnosis and prognosis of PCa [11,15,19-21,24]. How-
ever, most of the studies were related to Western. It is
well recognized that the incidence of PCa varies widely
among ethnic populations and countries [25]. In this
study, we focused proteomicsa n a l y s i so nt h et i s s u e s
obtained from prostate biopsies to identify new biomar-
kers of PCa in Chinese the population.
The development of the iTRAQ shot-gun proteomic
approach has offered the option to study differential
expression of proteins in perturbed systems. It can pro-
vide quantitative information from numerous experi-
mental approaches including affinity pull-downs, time-
course analyses, and discovery and confirmation of dis-
ease markers [16]. So far, iTRAQ has been used in
studying the proteomics of the tissue and the cell line of
PCa [15,19]. Garbis et al [15] conducted a study on 20
patients: 10 BPH and 10 PCa patients, and utilized
iTRAQ combined with 2DLC-MS/MS to identify 825
proteins. Of the differentially expressed proteins, 30
were shown to be up-regulated and 35 were down-regu-
l a t e di nP C a .I nt h e i rs t u d y ,t h es a m p l e sw e r eo b t a i n e d
from postoperative tissues. We agreed with the opinion
that proteomics analysis of prostate biopsies would
enable biomarker investigations of pathologically charac-
terized clinical samples [20]. So, we chose the samples
Figure 1 A representative MS/MS spectrum of PSA. The relative ratios of PSA between 116(PCa) and 114(BPH) was 1.31. PSA was identified
with 11 peptides abo-ve the 95% confidence. This Figure displays the MS/MS spectrum of one peptide from PSA. The peptide sequence:
FLRPGDDSSHDLNLLR is shown(The peptides above the 95% confidence are colored green and the peptides in the other colors have lower
confidence). BPH samples were labeled with 114 tags, PCa samples were labeled with the 116 tags, and BPH with local PIN samples were
labeled with 117 tags. The peptide fragments including b-ion and y-ion series are shown in A and B. The quantitation information of the
peptide is shown in C.
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Garbis, there were five same differentially expressed pro-
teins, of which, periostin and nucleophosmin were up-
regulated and the others were down-regulated including
collagen a-1(VI), zyxin, and vinculin. Additionally, In
our study, the two well known and clinically applied
proteins PSA and PAP were identified, a strong proof of
the reliability of iTRAQ approach in proteomics analysis
of PCa(Figure 1 and 2). The relative ratios of PSA and
PAP between 116(PCa) and 114(BPH) were 1.31 and
1.26, respectively. But, based on the condition of screen-
ing the differentially expressed proteins, there were no
difference of PSA and PAP between PCa(116) and BPH
(114), Additionally, PAP was reversely down-regulation
in the study of Garbis. We considered that the differ-
ence may partly be due to the different experiemental
conditions and experiemental errors.
Of the up-regulated proteins, subcellular location of
six proteins is mitochondria. They are Cytochrome c
oxidase polypeptide VIc(COX6C), Cytochrome c oxidase
subunit 5B(COX5B), ATP synthase subunit b(ATP5B),
Stress-70 protein(HSPA9), EF-Tu, 60 kDa heat shock
protein(HSPD1). Mitochondria have dual functions in
carcinogenesis, namely, cancer-associated changes in
cellular metabolism: the Warburg effect and the apopto-
sis-linked mitochondrial permeability transition pore
[26] Alterations in mitochondrial structure and function
may contribute to development of PCa. Cytochrome c
oxidase(COX) composed of 13 individual protein subu-
nits is at the heart of oxidative metabolism. Both
COX6C and COX5B are the subunits of COX which are
synthesized from nuclear DNA found on a variety of
chromosomes [27]. Krieg etal [27] reported that there
was an associated increase in the ratio of nuclear
encoded COX subunits to mitochondrially encoded
COX subunits in the tumor-derived cell lines including
PCa cells. ATP synthase is required for cellular energy
production. The expression of ATP synthase mRNA in
several malignant tumors including PCa is up-regulated
compared with the normal tissue [28]. ATP synthase is
reduced when a metastatic human prostate cell line is
converted to a slow growing cell line [29] and down-
regulated upon treatment of prostate cancer cell lines
with rapamycin [30]. Heat shock proteins (HSPs) protect
Figure 2 A representative MS/MS spectrum of PAP. The relative ratios of PAP between 116(PCa) and 114(BPH) was 1.26. PAP was identified
with 4 peptides above the 95% confidence. This Figure displays the MS/MS spectrum of one peptide from PAP. The peptide sequence:
FQELESETLKSEEFQK is shown(The peptides above the 95% confidence are colored green and the peptides in the other colors have lower
confidence). BPH samples were labeled with 114 tags, PCa samples were labeled with the 116 tags, and BPH with local PIN samples were
labeled with 117 tags. The peptide fragments including b-ion and y-ion seriesn are shown in A and B. The quantitation information of the
peptide is shown in C.
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pressed in several malignant tumors including PCa. So,
HSPs have been considered useful as diagnostic or prog-
nostic predictive factors in a variety of tumors. Further-
more, inhibiting the function of HSPs in tumor cells as
an attractive strategy in cancer treatment has been
reported [31]. EF-Tu belongs to EF-Tu/EF-1A subfamily
of the GTP-binding elongation factor family and pro-
motes the GTP-dependent binding of aminoacyl-tRNA
to the A-site of ribosomes(http://www.uniprot.org/). A
proteomics analysis about gastric carcinoma cell line
revealed high expression of EF-Tu [26]. The up-regula-
tion of EF-Tu was also detected in PCa by proteomics
analysis [21]. It has been reported that the proliferation,
invasion and migration of PCa Cells were inhibitied by
down-regulating EF-1A expression [9]. Our results pro-
vide clues as to the mechanism of the mitochondrial
changes at the protein level in PCa. So, the mitochon-
drial proteins may serve as potential biomarkers of PCa.
The proteins found to be down-regulated in our study
included several differentiation markers of smooth mus-
cle(SM) such as Desmin, Vimentin, Actin, gamma-enteric
smooth muscle, Laminin subunit gamma-1, Vinculin. All
these SM differentiation marks had been studied by
Wong etal [23]. In their study, immunohistochemical
methods revealed that the expression of SM markers was
markedly subdued and varied in the well-differentiated
tumors, whereas SM were totally absent in the moder-
ately to poorly differentiated tumors, except in regions
around vasculature. Our results of down-regulated pro-
teins were consistent with the changes of the SM differ-
entiation markers from their study. Interestingly,
heterogeneous nuclear ribonucleoprotein-H (hnRNP-H)
that plays a suppressive role in SM myogenesis is up-
regulated in our study [32]. This may have revealed the
mechanism of SM-epithelial interactions in carcinogen-
esis of PCa.
It is better and easier to understand the location, func-
tion and regulation of the differentially expressed pro-
teins by bioinformatics analysis. The top 5 components
for each category of GO in Figure 3 indicated that the
differentially expressed proteins in our study mainly
located in extracellular matrix with the function of bind-
ing were involved in muscle related BP, cytoskeleton
organization, anti-apoptosis and cell adhesion. Addition-
ally, the top 5 regulation networks indicated that the
SP1, p53, YY1, androgen receptor(AR) and c-Myc were
5 important factors regulating the differentially
Figure 3 GO annotation of the differentially expressed proteins. The differentially expressed proteins were divided into 3 categories: cellular
component (CC), molecu-lar function (MF) and biological process(BP). Left: Each enumerated annotation is assi-gned by the enrichment score
represented as P value. Right: The top 5 components for CC, MF, BP of the differentially expressed proteins according to GO database are
shown.
Figure 4 The transcription regulation network of SP1. The top 1
transcription regu-lation network initiated through activation of SP1
was shown. SP1 was involved in the regulation of 18 differentially
expressed proteins. The up-regulated proteins were indic-ated in
red circles and blue circles were used to indicate the down-
regulated proteins.
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factors may play great roles in the oncogenesis and pro-
gression of PCa.
Periostin, also named osteoblast-specific factor 2
(OSF-2), which was originally identified in the mouse
osteoblastic cell line:MC3T3-E1 as a secreted matricel-
lular protein [33]. The sequence of periostin contain a
typical signal sequence, a cysteine-rich domain, a four-
fold fasciclin 1-like (FAS-1) domain and a C-terminal
domain [33,34]. The FAS-1 domain, an evolutionarily
ancient adhesion domain also exists in many proteins
such as big-h3, stabling I and II, MBP-70, algal-CAM
and periostin-like factor. Therefore, all those proteins
containing periostin with the FAS-1 domain belong to
the fasciclin family [35]. Additionally, periostin share
high homology in human and mouse with 89.2% over-
all amino acid identity and 90.1% identity in their
mature forms [36]. The periostin gene is located on
chromosome 3 in mouse, while the human periostin
gene is located on chromosome 13q encoding a pro-
tein of 835 amino acids with a molecular weight of 90
kDa [37].
Periostin can interact with other extracelluar matrix
scaffold proteins, such as fibronectin, tenascin C, col-
lagen type I, collagen type V and heparin. It has been
discovered to be a ligand for avb3a n davb5 integrins
inducing integrin-dependent cell adhesion and motility
[38]. Being highly expressed in periosteum, perichon-
drium, periodontal ligaments, the fascia of muscles,
articular surfaces of the epiphyseal cartilage and joint
ligaments [39,40], periostin is thought to play a potential
role in formation and structural maintenance of those
tissues [40]. Additionally, it has been reported that peri-
ostin expression is correlated with the developing and
the diseased heart [41].
Recently, periostin was found to be overexpressed in
various types of human cancers including non-small-
cell lung cancer, breast cancer, ovarian cancer, colon
cancer, head and neck cancer, pancreatic cancer, liver
cancer and neuroblastoma [36]. It is thought that peri-
ostin enhances tumor growth through multiple
Table 1 Differentially expressed proteins(PCa:BPH)
Accession Protein name Peptides
(95%)
116:114
Down-regulation
sp|P17661 Desmin 62 0.03
sp|O95810 Serum deprivation-response
protein 3
3 0.13
sp|
Q9BX66
Sorbin and SH3 domain-containing
protein 1
18 0.18
sp|P08670 Vimentin 65 0.19
sp|P51911 Calponin-1 43 0.20
sp|P04792 Heat shock protein beta-1 15 0.22
sp|P63267 Actin, gamma-enteric smooth muscle 191 0.24
sp|
Q969G5
Protein kinase C delta-binding
protein
6 0.24
sp|P12109 Collagen alpha-1(VI) chain 19 0.25
sp|P11047 Laminin subunit gamma-1 9 0.28
sp|O94875 Sorbin and SH3 domain-containing
protein 2
2 0.32
sp|P24821 Tenascin 7 0.35
sp|Q15942 Zyxin 4 0.35
sp|Q9Y490 Talin-1 21 0.36
sp|P02452 Collagen alpha-1(I) chain 92 0.38
sp|P18206 Vinculin 15 0.39
sp|P20774 Mimecan 6 0.40
sp|Q93052 Lipoma-preferred partner 12 0.41
sp|Q09666 Neuroblast differentiation-associated
protein AHNAK
62 0.42
sp|P07585 Decorin 12 0.43
sp|P98160 Basement membrane-specific heparan
sulfate proteoglycan core protein
17 0.44
sp|P30086 Phosphatidylethanolamine-binding
protein 1
7 0.47
sp|P06396 Gelsolin 20 0.49
sp|P12111 Collagen alpha-3(VI) chain 63 0.50
sp|P01834 Ig kappa chain C region 4 0.53
sp|P10909 Clusterin 3 0.54
Up-regulation
sp|P62241 40S ribosomal protein S8 2 1.53
sp|P31943 Heterogeneous nuclear
ribonucleoprotein H
3 2.17
sp|P11021 78 kDa glucose-regulated protein 27 2.21
sp|P09669 Cytochrome c oxidase polypeptide VIc 2 2.38
sp|P10606 Cytochrome c oxidase subunit 5B,
mitochondrial
7 2.70
sp|P06576 ATP synthase subunit beta,
mitochondrial
13 2.83
sp|P38646 Stress-70 protein, mitochondrial 11 2.91
sp|P21810 Biglycan 19 2.96
sp|P49411 Elongation factor Tu, mitochondrial 6 3.02
sp|P22314 Ubiquitin-like modifier-activating
enzyme 1
5 3.34
sp|P13667 Protein disulfide-isomerase A4 5 3.77
sp|Q5SSJ5 Heterochromatin protein 1-binding
protein 3
5 4.06
sp|P55327 Tumor protein D52 3 4.25
sp|Q99623 Prohibitin-2 3 4.57
Table 1 Differentially expressed proteins(PCa:BPH)
(Continued)
sp|P07237 Protein disulfide-isomerase 17 4.70
sp|
Q9NZN4
EH domain-containing protein 2 2 5.55
sp|P10809 60 kDa heat shock protein,
mitochondrial
25 5.97
sp|P06748 Nucleophosmin 10 7.94
sp|Q15063 Periostin 13 9.12
sp|Q00796 Sorbitol dehydrogenase 9 9.82
*The proteins written with bold words were the same differentially expressed
proteins between 116:114(PCa:BPH) and 116:117(PCa:BPH with local PIN).
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Page 8 of 11pathways such as promoting cell proliferation, evasion
of apoptosis, limitless replicative potential, genomic
instability and induction of angiogenesis [36]. Addi-
tionally, periostin overexpression is always correlated
with increased tumor invasion and metastasis [42]. It
is indicated that periostin can facilitate tumor invasion
and metastasis by the process of epithelial-mesenchy-
mal transition(EMT) which enables epithelial cancer
cells to acquire invasive and metastatic potential [36].
So far, Only two studies have reported that the high
stromal expression of periostin was clearly and signifi-
cantly correlated with highg r a d ea n dh i g hs t a g eo f
PCa [43,44]. In our study, periostin was screened by
proteomics analysis of the tissues of prostate biopsy.
Then, the overexpression of periostin in PCa was verti-
fied by western blotting and immunohistochemical
staining(Figure 5). Our results of immunohistochemical
staining indicated that high expression of periostin was
mainly present in the stroma of PCa(Table 3). Based
on the result of this study along with the above two
studies, periostin may become a promising biomarker
for the diagnosis and prognosis of PCa.
Conclusion
Our study indicates that the iTRAQ technology is a new
strategy for global proteomics analysis of the tissues of
PCa. A significant up-regulation of periostin in PCa
compared to BPH may offer clues of not only a promis-
ing biomarker for the prognosis of PCa but also a
potential target for therapeutical intervention. However,
the role of periostin in the development and invasion of
PCa is in need of further in-depth study.
Abbreviations
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Table 2 Differentially expressed proteins(PCa:BPH with
local PIN)
Accession Protein name Peptides
(95%)
116:117
Down-regulation
sp|P17661 Desmin 62 0.03
sp|P24844 Myosin regulatory light polypeptide
9
10 0.14
sp|O95810 Serum deprivation-response
protein 3
3 0.16
sp|
Q9BX66
Sorbin and SH3 domain-
containing protein 1
18 0.20
sp|P09493 Tropomyosin alpha-1 chain 60 0.21
sp|
Q969G5
Protein kinase C delta-binding
protein
6 0.28
sp|P51911 Calponin-1 43 0.29
sp|P18206 Vinculin 15 0.30
sp|P15309 Prostatic acid phosphatase 4 0.32
sp|Q15942 Zyxin 4 0.36
sp|P02671 Fibrinogen alpha chain 18 0.37
sp|P07305 Histone H1.0 6 0.37
sp|Q9Y490 Talin-1 21 0.50
sp|P30101 Protein disulfide-isomerase A3 33 0.58
Up-regulation
sp|Q09666 Neuroblast differentiation-associated
protein AHNAK
62 1.91
sp|P00367 Glutamate dehydrogenase 1,
mitochondrial
10 2.19
sp|P13667 Protein disulfide-isomerase A4 5 2.19
sp|P10606 Cytochrome c oxidase subunit
5B, mitochondrial
7 2.31
sp|P12111 Collagen alpha-3(VI) chain 63 2.33
sp|P31943 Heterogeneous nuclear
ribonucleoprotein H
3 2.42
sp|P61604 10 kDa heat shock protein,
mitochondrial
9 2.44
sp|P49411 Elongation factor Tu,
mitochondrial
6 2.86
sp|P11021 78 kDa glucose-regulated protein 27 2.93
sp|P35579 Myosin-9 29 3.25
sp|P07237 Protein disulfide-isomerase 17 3.44
sp|P21810 Biglycan 19 3.53
sp|P22392 Nucleoside diphosphate kinase B 5 3.73
sp|P10809 60 kDa heat shock protein,
mitochondrial
25 5.55
sp|Q15063 Periostin 13 5.55
sp|P62906 60S ribosomal protein L10a 6 5.97
sp|P06748 Nucleophosmin 10 6.37
sp|
Q9BXN1
Asporin 7 7.38
sp|Q00796 Sorbitol dehydrogenase 9 9.12
*The proteins written with bold words were the same differentially expressed
proteins between 116:114(PCa:BPH) and 116:117(PCa:BPH with local PIN).
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